Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KMT2C drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KMT2C (SET Domain) Recombinant Protein High purity (>95%), Endotoxin Controlled, Sequence Verified. Active domain for methyltransferase assays. |
View KMT2C Products |
| Gene Delivery | KMT2C Promise-ORF / Lentivirus Full-length or domain-specific ORF for stable cell line generation. |
View KMT2C Products |
| Benchmark Ab | Anti-KMT2C Recombinant Antibody Recombinant positive control for Western Blot, ChIP, and ELISA. |
View KMT2C Products |
| Validator | KMT2C siRNA Set For knockdown verification in functional validation assays. |
View KMT2C Products |
| Related Target A | KMT2D Highly homologous methyltransferase; critical for selectivity profiling and counter-screening. |
View KMT2D Products |
| Related Target B | WDR5 Core COMPASS complex adapter protein; essential partner for KMT2C methyltransferase activation. |
View WDR5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| SET Domain Selectivity Screening | Highly purified KMT2C and KMT2D SET domain proteins (>95% purity by SDS-PAGE) for robust differential binding assays. |
| COMPASS Complex Reconstitution | Sequence-verified core adapter proteins (WDR5, RBBP5, ASH2L) available for in vitro enzyme activity assembly. |
| Lack of Controls | Clinical-grade benchmark antibodies and specific siRNA knockdown pools included for target validation. |
| False Positives | Sequence-verified wild-type and catalytic mutant proteins to rule out non-specific binding in small molecule screens. |
Live KMT2C R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KMT2C therapeutics is intensifying, with major players shifting focus from traditional chromatin regulators to targeted synthetic lethality and epigenetic rewriting. As first-generation therapies targeting the wider COMPASS complex reach the clinic, the next wave of R&D is targeting the specific catalytic SET domain of KMT2C or exploiting KMT2C-deficient tumor profiles.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Epizyme (Ipsen), Ryvu Therapeutics | Solid Tumors, AML, Breast Cancer | Selectivity Assay (Need KMT2C SET domain vs KMT2D/KMT2A panel) |
| PROTACs / Degraders | Arvinas, Academic spin-offs | Hormone-Resistant Prostate/Breast Cancer | Ubiquitination & Degradation Validation (Need high-purity full-length or domain proteins) |
| Synthetic Lethal Agents | AstraZeneca, GSK | KMT2C-mutant cancers (bladder, colorectal) | Isogenic cell line validation (Need Lentivirus for stable cell line construction) |